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Abstract  18 
 19 
In many communities, cannabis is perceived as a low-risk drug, leading to political 20 
lobbying to decriminalise its use. However, acute and chronic cannabis use has been 21 
shown to be harmful to several aspects of psychological and physical health, such as 22 
mood states, psychiatric outcomes, neurocognition, driving and general health. 23 
Furthermore, cannabis is highly addictive, and the adverse effects of withdrawal can lead 24 
to regular use. These in turn have adverse implications for public safety and health 25 
expenditure. Although the cannabinoid cannabidiol (CBD) has been shown to have 26 
positive health outcomes with its antioxidant, anticonvulsant, anti-inflammatory and 27 
neuroprotective properties, high-potency cannabis is particularly damaging due to its high 28 
tetrahydrocannabinol (THC), low CDB concentration. It is this high-potency substance 29 
that is readily available recreationally. While pharmaceutical initiatives continue to 30 
investigate the medical benefits of CDB, “medicinal cannabis” still contains damaging 31 
levels of THC. Altogether, we argue there is insufficient evidence to support the safety of 32 
cannabis and its subsequent legalisation for recreational use. Furthermore, its use for 33 
medicinal purposes should be done with care. We argue that the public conversation for 34 
the legalisation of cannabis must include scientific evidence for its adverse effects. 35 
 36 
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1. Introduction 40 
The World Health Organisation (WHO)(World Health Organization, 2016), as well as the 41 
United Nations Office on Drugs and Crime (United Nations Office of Drugs and Crime, 42 
2016), have recently handed down reports outlining the damaging effects of cannabis on 43 
humans, as well as the current recommendations as to the use and misuse of the 44 
psychoactive substance for recreational and medicinal purposes. It is noted that while the 45 
majority of participating United Nations countries are considered signatories to 46 
international treaties on the control of narcotic drugs (including cannabis), such as the 47 
United Nations Convention Against Illicit Traffic in Narcotic Drugs and Psychotropic 48 
Substances, several discrepancies between regions regarding the legal, personal and 49 
psychobiological implications of cannabis consumption remain, and individual countries 50 
have largely developed discrete control measures and guidelines for cannabis use. In 51 
recent years, well-funded campaigns to decriminalise recreational use of cannabis have 52 
portrayed cannabis as a relatively benign substance, thereby creating a degree of conflict 53 
between the recommendations set out by the treaties and those outlined by individual 54 
governances. This has led to the legalisation of cannabis consumption in a number of 55 
regions, including the Netherlands, several USA states and Uruguay. Furthermore, 56 
“medicinal cannabis” is increasingly accepted as an adjunct treatment for chronic pain, 57 
epilepsy and for the reduction of the adverse side effects of treatments such as 58 
chemotherapy (Iskedjian, Bereza, Gordon, Piwko, & Einarson, 2007; Machado Rocha, 59 
Stefano, De Cassia Haiek, Rosa Oliveira, & Da Silveira, 2008; Porter & Jacobson, 2013; 60 
Rog, Nurmikko, Friede, & Young, 2005). For those working in the field of drug 61 
dependency, this move to change legal policy around cannabis distribution and 62 
consumption is concerning, given the lack of scientific evidence regarding the specific 63 
adverse effects cannabis has on physical, psychological and neurocognitive health.  64 
 65 
The drug cannabis is derived from the leaves and flowers of the Cannabis Sativa plant, 66 
and contain a class of compounds, called cannabinoids, that act upon cannabinoid 67 
receptors in the brain (CB1) and immune system (CB2). There are 13 main classes of 68 
cannabinoids, with the most extensively researched of these being tetrahydrocannabinol 69 
 4 
(THC) and cannabidiol (CBD). THC is the primary psychoactive component of cannabis, 70 
while CBD is a non-psychotropic component with some positive therapeutic effects. 71 
Cannabis is typically consumed by combining species of the cannabis plant and smoking 72 
as a cigarette (often referred to as a joint). Modern joints typically contain 150mg to 73 
300mg of THC, which is over 15 times the potency of joints in the 1960s and 70s 74 
(Ashton, 2001). When smoked, 50% of the THC is inhaled and absorbed through the 75 
lungs into the blood stream. When ingested orally, only 12-15% of the THC ingested 76 
reached the bloodstream (Ashton, 2001). The effects of as little as 2.5mg of THC can be 77 
felt within minutes after smoking, and with 30 minutes to 2 hours after ingesting (Ashton, 78 
2001). The adverse effects and potential health benefits of cannabis and cannabidiol are 79 
summarised in Table 1 and Table 2, respectively, and are discussed in detail in this 80 
review.  81 
 82 
This review provides an overview of the current evidence regarding some of the key 83 
adverse physical, psychological and neurological effects of cannabis consumption. In 84 
particular, we critique the widespread belief that consumption of cannabis may be 85 
beneficial overall. Although some of the adverse effects of cannabis are well recognised, 86 
there is a lack of awareness regarding cannabis dependency and withdrawal, and the 87 
effect of cannabis on mood states, psychiatric outcomes, neurocognition, driving and 88 
general health. We also review the literature regarding the possible health benefits of 89 
cannabis.  90 
 91 
2. Acute effects of cannabis 92 
Cannabis use can engender a range of positive mood effects which make it attractive for 93 
users. Acute effects often include feeling of happiness, relaxation and calmness, 94 
contemplativeness, creative thoughts, humorousness, social disinhibition and sociability 95 
(Green, Kavanagh, & Young, 2003; Titus, Godley, & White, 2007; Wachtel, ElSohly, 96 
Ross, Ambre, & de Wit, 2002). The acute effects of cannabis may last for a couple of 97 
hours, and are often extended by further usage, thus heavy dependent users spend much 98 
of their time each day in this drug-replete state. Cannabis can, however, also generate a 99 
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range of negative mood states, including feelings of anxiety, tension, agitation with a 100 
racing heart, mental confusion, forgetfulness, unsteadiness, suspiciousness and paranoia 101 
(Hall, 2015; Volkow, Baler, Compton, & Weiss, 2014). These effects can be present even 102 
with infrequent cannabis use (Hall & Pacula, 2003). A study of over 3,000 students found 103 
that of those who had consumed cannabis at least once, only 17% had experienced at least 104 
one negative outcome, while 76% experienced at least one positive outcome (Le Strat et 105 
al., 2009). The study also found that those reacting positively in their early experience 106 
with cannabis are more likely to become regular users, up to 28.7 times more likely than 107 
those who do not experience any positive outcomes (Le Strat et al., 2009). Hence, the 108 
nature of the effects of cannabis allows it to be highly susceptible to cannabis dependence 109 
(Coffey, Carlin, Lynskey, Li, & Patton, 2003; Le Strat et al., 2009), which may lead to 110 
subsequent addiction (Coffey et al., 2003). 111 
 112 
3. Cannabis withdrawal  113 
The period of post-drug recovery is a crucial time for any psychoactive substance, since 114 
the on-drug mood gains are typically followed by a period of negative moods (Parrott, 115 
Morinan, & Moss, 2008). This pattern is readily demonstrated by tobacco smokers, since 116 
their moods vacillate over time – becoming positive on smoke-inhalation, then worsening 117 
as time lapses between cigarettes (Parrott, 1994). Vandrey, Budney, Moore, and Hughes 118 
(2005) compared the mood effects of cannabis withdrawal and tobacco withdrawal, 119 
finding a similarity in the magnitude and time course of the withdrawal effects. The 120 
unpleasant mood effects of cannabis withdrawal for two to seven days often include 121 
reduced appetite, weight loss, difficulty sleeping, and increased anxiety, irritability, 122 
restlessness, physical agitation, anger, aggression, and depression (Allsop, Copeland, 123 
Lintzeris, & et al., 2014; Budney, Hughes, Moore, & Novy, 2001; Vandrey et al., 2005). 124 
These negative psychobiological sequelae can make it difficult for regular cannabis users 125 
to quit, however, more extended periods of cannabis withdrawal (up to 30 days) has been 126 
shown to normalise these characteristics to baseline levels (Vandrey et al., 2005). 127 
Nevertheless, the negative effects of cannabis withdrawal can lead to cannabis 128 
dependence. 129 
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 130 
4. Cannabis dependence  131 
Cannabis use has been demonstrated as a relatively normative behaviour, particularly in 132 
young adults. However, when used regularly (i.e. weekly), the risk of cannabis 133 
dependence increased at a rate of 4.9:1. There are several factors that contribute to the 134 
progression from recreational cannabis user to cannabis dependence, including: avoiding 135 
withdrawal, unintentional use, persistent desire and increased tolerance to the effects of 136 
cannabis (Coffey et al., 2002; Coffey et al., 2003). Additional risk factors include regular 137 
cigarette smoking, antisocial behaviour and being male (Coffey et al., 2002; Coffey et al., 138 
2003). The severity of smoking behaviour and presence of psychiatric ill-health in 139 
adolescence has been shown not to predict later cannabis dependence (Coffey et al., 140 
2003). According to the DSM 5, substance use disorder includes a spectrum of 141 
behaviours ranging from substance abuse to substance dependence, whereby mental and 142 
physiological changes lead to increased tolerance and withdrawal symptoms.  Substance 143 
addiction is a term used to represent the severity of substance use disorder symptoms; 144 
generally, an extreme degree of dependence that leads to a fixation on substance-seeking 145 
behaviour (DSM 5, 2013). For most recreational users, however, a substance use disorder 146 
does not eventuate (Coffey et al., 2003).  147 
 148 
It has been estimated that over 300,000 and 69,000 individuals enter treatment for a 149 
cannabis use disorder each year in the United States of America and Europe, respectively 150 
(European Monitoring Centre for Drugs and Drug Addiction, 2016; Herrmann, Weerts, & 151 
Vandrey, 2015). Mood states experienced during withdrawal are often salient predictors 152 
of treatment success rates and rates of remission, with higher cannabis withdrawal 153 
symptom scores frequently associated with poorer treatment outcomes (Budney, Hughes, 154 
Moore, & Vandrey, 2004). These adverse mood effects on remission can lead to a strong 155 
dependency on the drug (Hall & Pacula, 2003); around one in ten people who report ever 156 
having used cannabis will go on to develop a clinically defined cannabis use disorder 157 
(Wagner & Anthony, 2002), and considerably more can be defined as subclinical.  158 
 159 
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There are estimated to be around 13.1 million cannabis dependent individuals globally, 160 
with peak prevalence among 20-24 year olds, and a general preponderance of males 161 
overall (Degenhardt et al., 2013). Young people tend to be more susceptible to cannabis 162 
dependence, particularly when use begins in early adolescence. A study found that 163 
cannabis use before the age of 17 years led individuals to be 18 times more likely to 164 
develop dependence by the age of 30 than those who began using later in adulthood 165 
(Silins et al., 2014). While adolescent cannabis use is a major challenge, those over the 166 
age of 50 were the fastest growing cannabis-using age group in the past two Australian 167 
population surveys (AIHW, 2014). Finally, dependency risk increases with frequency of 168 
use with as many as 65% of recreational cannabis users reporting some degree of 169 
cannabis dependence, which was more common for frequent cannabis users (2+ times per 170 
week) than by the occasional users (Terry, Wright, & Cochrane, 2007), and up to 50% of 171 
daily cannabis users have been reported to become dependent (Coffey et al., 2002). 172 
Living alone, self-medication and negative life events are additional predictors of 173 
cannabis dependence (van der Pol et al., 2013).  174 
 175 
Cannabis dependence increases the risk of suffering from the negative side effects such as 176 
short-term memory impairment, mental health problems, and respiratory diseases (in the 177 
event of smoking). Dependence can also have negative financial, social, relationship 178 
(such as with family and friends), and employment implications (Coffey et al., 2003). 179 
Cannabis use disorder is commonly comorbid with other substance use disorders and 180 
mental health conditions, and should be assessed and treated concurrently in order to 181 
improve longer-term patient outcomes (Copeland, Clement, & Swift, 2014). Cannabis use 182 
disorder, both at a clinical and a subclinical level, often goes undetected or is detected 183 
indirectly through the presentation of comorbid conditions.  Of the 65% of recreational 184 
cannabis users reporting some degree of cannabis dependence above, only 2.6% of the 185 
sample had sought clinical treatment (Terry et al., 2007). 186 
 187 
Like other substance use disorders, continuous abstinence relapse rates are high among 188 
cannabis users, and many patients do not show a positive treatment response, indicating 189 
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that cannabis dependence is difficult to treat (McRae, Budney, & Brady, 2003). Evidence-190 
based pharmacotherapies for cannabis use disorder are not currently available, despite 191 
recent studies indicating promising early results for agonist therapies (Allsop et al., 2014). 192 
Limited open-label studies have indicated clinical efficacy for drug therapies such as 193 
buspirone, dronabinol, fluoxetine, lithium, lofexedine, and rimonabant (Vandrey & 194 
Haney, 2009), however, comprehensive and systematic clinical trials assessing both their 195 
acute and long-term efficacy is currently lacking. A 2014 meta-analysis concluded that 196 
the evidence supporting the use of some pharmacotherapies such as selective serotonin 197 
reuptake inhibitor antidepressants, mixed action antidepressants, anticonvulsants and 198 
mood stabilisers for the treatment of cannabis dependence disorders is incomplete 199 
(Marshall, Gowing, Ali, & Le Foll, 2014).  200 
 201 
Psychotherapeutic interventions are currently the most widely researched and utilised 202 
treatment approach to address cannabis dependence, particularly cognitive behavioural 203 
therapy (CBT) treatment. In fact, CBT treatment has been shown to be most effective for 204 
those wishing to reduce or abstain from cannabis, but not for polydrug users (Dutra et al., 205 
2008). Predictors of an individual’s success in treatment include inter-individual active 206 
coping strategies and distress tolerance (Copeland et al., 2014), as well as a desire to 207 
regain control over one’s life, and to reduce associated cognitive and health consequences 208 
of cannabis use (Chauchard, Septfons, & Chabrol, 2013).  209 
 210 
5. Psychiatric outcomes 211 
The world’s oldest pharmacopeia, attributed to Emperor Shen Nung in China, noted that 212 
although cannabis had some useful medicinal properties: “If taken in excess it will 213 
produce visions of devils” (Zuardi, 2006) p154. Modern research has empirically 214 
confirmed this. Acute and chronic cannabis use are associated with higher rates of 215 
psychiatric pathologies such as stress, anxiety, depression and psychosis (Volkow et al., 216 
2014).  217 
 218 
5.1. Acute outcomes 219 
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Acute adverse effects of cannabis consumption include disordered thoughts and 220 
cognitions (including paranoia), a sense of depersonalisation, fear of dying, and an 221 
impending feeling of panic (Ashton, 2001). D'Souza et al. (2004) administered the 222 
cannabinoid THC to recreational cannabis users without a prior psychiatric history, and 223 
reported significant increases in the positive and negative symptoms of schizophrenia as 224 
measured by the Positive and Negative Symptom Scale (PANSS). Some of the subjective 225 
experiences described by the participants are presented in D'Souza et al. (2004). Increased 226 
positive symptoms scores as measured by the PANSS following administration of THC 227 
are also related to increases in high frequency brain oscillations (Nottage et al., 2015). 228 
This increase in positive symptoms tends to reduce as the acute effects of cannabis wear 229 
off (D'Souza et al., 2004; Nottage et al., 2015), however, for regular users, these periods 230 
may be cumulatively damaging. Moreover, the cannabis use has been shown to increase 231 
schizophrenia and bipolar symptoms, while cannabis use is used by many to “self-232 
medicate” against adverse symptoms and pharmaceutical side effects (N. Wilson & 233 
Cadet, 2009). Indeed, there is extensive clinical evidence for a heightened risk of 234 
developing schizophrenia in regular and/or chronic users (Andréasson, Engström, 235 
Allebeck, & Rydberg, 1987; Malone, Hill, & Rubino, 2010; Paparelli, Di Forti, Morrison, 236 
& Murray, 2011).  237 
 238 
Although psychiatric conditions have been shown not to predict later cannabis use 239 
disorder, frequency of use was slightly increased for those with a clinical condition 240 
(Coffey et al., 2003). Furthermore, increased use of cannabis has been associated the 241 
presence of psychiatric and mood disorders such as anxiety and depression (Wittchen et 242 
al., 2007).  243 
 244 
5.2. Chronic outcomes 245 
Cannabis is one of several psychoactive drugs known to induce psychosis among heavy 246 
users and those sensitive to the psychoactive properties of cannabis (Paparelli et al., 247 
2011), and the cannabinoid THC is thought to be responsible for the majority of the 248 
negative psychiatric and cognitive outcomes of chronic cannabis use (Crean, Crane, & 249 
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Mason, 2011; Volkow et al., 2014). The Swedish Conscript study was instrumental in 250 
first demonstrating an association between cannabis use and later development of 251 
schizophrenia (Andréasson et al., 1987). The study comprised 45,579 young armed-forces 252 
conscripts and found that those who consumed cannabis on more than 50 occasions were 253 
6 times more likely to develop schizophrenia over a 15-year period than their non-using 254 
counterparts. Fergusson, Horwood, and Swain-Campbell (2003) followed a birth cohort 255 
of 1,265 children over 21 years, and found that those with cannabis dependence had an 256 
increased risk of psychotic symptoms. A seminal review conducted by Moore et al. 257 
(2007), investigated the relationship between cannabis use and the occurrence of 258 
psychotic or affective mental health outcomes reported in longitudinal studies. Overall, 259 
the risk of adverse psychiatric outcomes for former cannabis users was significantly 260 
higher than adverse affective outcomes. The review also demonstrated a dose-response 261 
association between cannabis use and psychiatric outcomes; these effects were more 262 
pronounced among regular users (Moore et al., 2007). Finally, Le Bec, Fatséas, Denis, 263 
Lavie, and Auriacombe (2009) reinforced the link between cannabis use and the 264 
emergence of psychosis or psychotic symptoms in their review.  265 
 266 
Personality traits and psychiatric predispositions have been shown to modulate the 267 
relationship between cannabis use and psychiatric outcomes. Henquet et al. (2005) 268 
followed 2,437 young cannabis users who did or did not have a predisposition for 269 
psychosis and an increased risk of psychosis for both groups, but the increase was more 270 
pronounced for the predisposed group (23.8%) compared to the non-predisposed group 271 
(5.6%). In support of the previously reported studies, there was a significant effect of 272 
dosage; those who using cannabis less than monthly typically showed no increase in 273 
psychotic symptoms, while psychotic symptoms increased as frequency increased from 274 
one to two times per week to almost daily use. 275 
 276 
Cannabis use is also associated with higher rates of other chronic mental health problems, 277 
such as stress, depression, and anxiety (Bovasso, 2014; O’Connor, Schwid, Herrmann, 278 
Markman, & Dworkin, 2008; Patton et al., 2002; Richardson, 2010; Van Laar, Van 279 
 11 
Dorsselaer, Monshouwer, & De Graaf, 2007), and mania has been shown to increase 280 
more than two-fold in a non-clinical population (Henquet, Krabbendam, de Graaf, ten 281 
Have, & van Os, 2006; Richardson & Garavan, 2011). In several of these studies, dosage 282 
effects were again noted, with heavier users found to be most at risk of adverse 283 
psychiatric outcomes. Significant, albeit somewhat weaker association have also been 284 
noted between cannabis use and later development of hypomania symptomology among 285 
non-clinical samples of adolescents (Wittchen et al., 2007). It is important to note that 286 
research of this nature often involves complex interactions with a number of 287 
environmental and intra-individual factors such as personality traits and clinical 288 
predisposition factors, and thus definitive clinical characterisations of at-risk populations 289 
is often problematic (Richardson, 2010). 290 
 291 
6. Neurocognitive effects 292 
While cognition is acutely impaired after smoking cannabis, there is increasing evidence 293 
that such impairment can persist beyond the period of acute intoxication. Acute cognitive 294 
outcomes include disrupted immediate and delayed word recall, increased distractibility, 295 
poor verbal fluency, and poor working memory (D'Souza et al., 2004). Among chronic 296 
users, memory impairment is most consistently reported, particularly free recall, delayed 297 
recall and recognition (Grant, Gonzalez, Carey, Natarajan, & Wolfson, 2003). Other 298 
affected cognitive functions include attention, inhibition, executive function, decision-299 
making and psychomotor function (Jager, Block, Luijten, & Ramsey, 2010; Pope et al., 300 
2001; Ramaekers, Kauert, Theunissen, Toennes, & Moeller, 2008). Cognitive dysfunction 301 
in long-term or heavy cannabis users has been shown to increase as a function of 302 
frequency of use, age of use initiation, and the urine/blood concentration of THC at the 303 
time of testing (Pope et al., 2001; Yücel et al., 2008), and a dose-response cognitive effect 304 
has been shown to exists among abstinent heavy users (Bolla, Brown, Eldreth, Tate, & 305 
Cadet, 2002). Evidence from animal and human studies suggests that the adolescent brain 306 
is more susceptible to the adverse effects of cannabis, leading to greater cognitive 307 
impairment. Even in abstinent users, marked deficits in memory performance are reported 308 
for frequently using versus non-using adolescents (Jager et al., 2010).  309 
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 310 
Cognitive dysfunction in long-term users tends to persist for at least one month following 311 
the cessation of cannabis use (Bolla et al., 2002); however, the extent of damage and time 312 
course of recovery over the lifespan has not yet been accurately mapped. While a number 313 
of studies suggest that some cognitive functions appear to recover within a few weeks 314 
(Hanson et al., 2010; Pope et al., 2001), other, more limited research, has demonstrated 315 
symptomatic persistence in some cognitive domains one month post-drug abstinence (or 316 
longer) (Bolla et al., 2002). Greater decline in IQ over 20-30 years has been reported 317 
among those who commenced using cannabis during adolescence, and persisted even 318 
among those who had ceased or greatly reduced their use later in adulthood, controlling 319 
for socioeconomic status (Meier et al., 2012). 320 
 321 
Estimation of the degree of cognitive deficits beyond one month post-abstinence are 322 
currently unclear, as follow-up studies seldom track performance beyond a one- or two-323 
month period, and a large variation in assessment sessions post-abstinence exist. To our 324 
knowledge, the longest follow-up protocol examined among longitudinal studies was that 325 
outlined by Meier et al. (2012), which employed a 38-year follow-up schedule. Often, age 326 
of initiation and total years of use are important predictors of residual cognitive effects 327 
associated with cannabis use, suggesting that cessation during critical developmental 328 
periods of adolescence may improve outcomes later in life (Meier et al., 2012). Clearly, 329 
longitudinal studies are needed to elucidate the long-term effects of cannabis use on 330 
cognitive functioning, while effectively controlling for potential confounding factors. 331 
 332 
7. Neurological effects 333 
Clinical research has suggested changes in brain morphology due to prolonged exposure 334 
to cannabis, and evaluation of these alterations in brain function following chronic 335 
cannabis use are often derived from neuroimaging studies. Abnormalities in brain regions 336 
with a high density of cannabinoid receptors, such as the prefrontal regions, 337 
hippocampus, amygdala and cerebellum, have been consistently shown, as well as overall 338 
reduced regional brain volume and increased grey matter (Lorenzetti, Solowij, & Yücel, 339 
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2016). Using magnetic resonance imaging (MRI) and positron emission tomography 340 
(PET) it was revealed that those commencing cannabis use prior to 17 years of age had 341 
reduced overall cortical size and percentage grey matter, and increased percentage of 342 
white matter volume compared to those who commence use later (W. Wilson et al., 343 
2000). Structural neuroimaging studies have identified reduced grey matter in the medial-344 
temporal, orbitofrontal, temporal pole, parahippocampal gyrus, insula and cerebellar 345 
regions (Batalla et al., 2013; Battistella et al., 2014; Lorenzetti, Solowij, Fornito, Ian 346 
Lubman, & Yucel, 2014), although, the evidence for significant differences between 347 
cannabis users and non-users is largely mixed (Lorenzetti et al., 2014). Reduced white 348 
matter density among regular users (Zalesky et al., 2012), dose-related reductions in 349 
hippocampal and amygdala volumes (Yücel et al., 2008), and shape alterations to the 350 
nucleus accumbens have also been reported (Gilman et al., 2014).   351 
 352 
Further research into potential structural risk factors for young people requires further 353 
attention. To our knowledge, only one such study exists, which tracked adolescent brain 354 
structure from 12 to 16 years of age, and found that those who began smoking cannabis 355 
had significantly smaller orbitofrontal cortex volumes at 12 years of age. Such differences 356 
were not seen in the amygdala, hippocampus, and anterior cingulate cortex (Cheetham et 357 
al., 2012). These findings suggest that structural abnormalities in select brain regions may 358 
contribute to an increased risk for later cannabis use, however, considerably more 359 
longitudinal research is required before more definitive conclusions can be drawn 360 
regarding the strength of these associations.  361 
 362 
8. Adverse health effects 363 
Cannabis consumption has a damaging effect on several bodily functions, including the 364 
cardiovascular, respiratory, immune, endocrine and reproductive systems (Adams & 365 
Martin, 1996; Ashton, 2001; Volkow et al., 2014). Some adverse effects, such as those on 366 
the respiratory system, can be attributed to the mechanism of cannabis consumption 367 
(smoke inhalation) (Ashton, 2001), whereas others, such as damage to the immune 368 
system, are due more directly to the cannabinoids (Adams & Martin, 1996).  369 
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 370 
8.1. Pulmonary/respiratory pathology 371 
When cannabis in smoked, carcinogens and other gaseous by-products are released, 372 
including vinyl chlorides, phenols, nitrosamines and reactive oxygen species (ROS), 373 
which are similar to those released by tobacco cigarette smoke (Ashton, 2001; Taylor & 374 
Hall, 2003; Taylor, Poulton, Moffitt, Ramankutty, & Sears, 2000). These have a 375 
comparable pro-inflammatory, histopathological and synergistic effects (Taylor & Hall, 376 
2003; Zhang et al., 1999). Cannabis smoking is associated with inflammation of the 377 
airways and compromised lung function, thus users are susceptible to bronchial-related 378 
conditions (Tashkin, 2013) and chronic respiratory diseases, such as pneumonia (Tashkin, 379 
2005). Meta-analyses support this assertion, noting consistently higher isolated 380 
respiratory complications among smokers, such as increased phlegm, wheezing and 381 
coughing (Tetrault et al., 2007). 382 
 383 
8.2. Cancers 384 
Several population-based case-control and cohort studies of cannabis smokers report 385 
increased rates of the various cancers that are often observed in tobacco smokers, such as 386 
oral (Llewellyn, Linklater, Bell, Johnson, & Warnakulasuriya, 2004), lung (Aldington et 387 
al., 2008) and head and neck cancer (Zhang et al., 1999); reduced pulmonary function is 388 
also reported (Aldington et al., 2007). The WHO report evidence for increased risk of 389 
upper digestive tract cancers, respiratory cancers and testicular cancer, as well as prostate 390 
and cervical cancer (World Health Organization, 2016). It is important to note that as 391 
cannabis is mixed with tobacco for smoking, it is difficult to differentiate the effect of 392 
cannabis from tobacco on respiratory health. 393 
 394 
8.3. Cardiovascular pathology 395 
Cardiovascular changes associated with low-moderate levels of cannabis include a dose-396 
dependent elevation of resting heart rate (50-60% increase) and subsequent moderate 397 
increase in blood pressure (Menkes, Howard, Spears, & Cairns, 1991), and increased 398 
vascular constriction/constriction (Sidney, 2002). Higher doses of cannabis can lead to 399 
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orthostatic hypotension and bradycardia (Jones, 2002; Pratap & Korniyenko, 2012). 400 
These effects increase as THC plasma concentration peaks (typically 10-15 minutes), and 401 
can remain elevated for up to 3 hours post-ingestion (Sidney, 2002). Peripheral effects, 402 
such as reduced circulatory responses (Benowitz & Jones, 1975) and compromised 403 
middle cerebral artery blood velocity (CBV) (Mathew, Wilson, Humphreys, Lowe, & 404 
Wiethe, 1992), have also been reported. Cannabis use has been associated with more 405 
severe cardiovascular events, such as acute myocardial infarction among older 406 
(Mittleman, Lewis, Maclure, Sherwood, & Muller, 2001) and some young users 407 
(Caldicott, Holmes, Roberts-Thomson, & Mahar, 2005), as well as ischemic stroke 408 
(Wolff et al., 2011) and cerebral infarction (Moussouttas, 2004).  409 
 410 
Chronic cardiovascular complications resulting from cannabis use is likely attributed to 411 
lowered cardio-pulmonary thresholds as a direct result of drug use. Despite this, relative 412 
to the acute implication of cannabis use, there are considerably fewer studies 413 
systematically assessing long-term cardiovascular outcomes among chronic cannabis 414 
users, and inconsistencies regarding methodological approaches somewhat preclude 415 
accurate comparisons to be drawn among available clinical and epidemiological research. 416 
Observations of the chronic cardiovascular effects of cannabis use are often impeded by 417 
issues of tolerance, level of exposure and intra-individual differences. Indeed, the 418 
cardiovascular implications among frequent cannabis users are found to be somewhat 419 
attenuated as a function of exposure, with some degree of cardiac compensation observed 420 
following extended use (Renaud & Cormier, 1986). Meta analytic studies assessing the 421 
collective risk of cardiovascular dysfunction due to extended cannabis use are notably 422 
lacking, with much of the available reviews being largely descriptive in nature [for 423 
example see (Pratap & Korniyenko, 2012; Sidney, 2002)]. Thus, additional 424 
comprehensive systematic evaluations that effectively collate clinical and experimental 425 
findings are urgently required if these associations are to be confirmed, and if appropriate 426 
clinical and public health recommendations are to be made.  427 
 428 
8.4. Pregnancy and childhood cancer 429 
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Trans-generational assessment of the effect of paternal and maternal cannabis use during 430 
the gestational period and preceding conception on the cancer rates of the child have 431 
indicated as much as an 11-fold increased risk of childhood acute nonlymphoblastic 432 
leukaemia (Robison et al., 1989), astrocytoma (Kuijten, Bunin, Nass, & Meadows, 1990) 433 
and childhood rhabdomyosarcoma (Grufferman, Schwartz, Ruymann, & Maurer, 1993). 434 
However, the data was generally acquired through hospital surveys, and concomitant 435 
tobacco use was often not assessed, and dose-response evaluations were often not 436 
included, thus preclude the ability to generalise the observed results (Hashibe et al., 2005; 437 
Mehra, Moore, Crothers, Tetrault, & Fiellin, 2006). 438 
 439 
Cannabis consumption causes health burden across several bodily systems, and are not 440 
only limited to those discussed above. Compromised pulmonary/respiratory and 441 
cardiovascular functioning, and increased rates of cancer, account for significant health 442 
and economic burden among cannabis users. Clinical and experimental research has 443 
indicated significant acute and chronic health effects resulting from cannabis use, 444 
however, comprehensive assessments their magnitude are currently lacking. Furthermore, 445 
many experimental studies have marked methodological limitations. Increasing rates of 446 
cannabis consumption among the general population present a growing area of concern 447 
for acute and long-term healthcare, and may have significant implications for health 448 
providers, and public and private healthcare systems. Additional resources are therefore 449 
urgently needed to adequately describe and evaluate the scope of this potential health 450 
problem. 451 
 452 
9. Adverse effects on cognitive-motor skills and implications for road safety 453 
Cannabis produces dose and experience-dependent effects on a variety of 454 
neurobehavioural and performance indices of high clinical relevance to public health 455 
(Hart, van Gorp, Haney, Foltin, & Fischman, 2001; O'Leary et al., 2002; Ramaekers et al., 456 
2008; Ramaekers et al., 2006). Studies indicate that cannabis use produces a measureable 457 
effect on several safety-sensitive cognitive-motor abilities, including (but not limited to) 458 
body sway and imbalance (Liguori, Gatto, & Robinson, 1998), behavioural execution, 459 
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and aspects of physical competences (Huestis, 2002). Accordingly, much of the data 460 
pertaining to the neurobehavioural consequences of cannabis intoxication refer to 461 
impairments associated with high-risk routine daily activities, such as driving a motor 462 
vehicle, that engender these skills. Driving is a complex neurobehavioural task that 463 
necessitates accurate perception, appropriate judgement, adequate response time and 464 
suitable physical capability. Survey studies indicate that between 10% (Mura et al., 2003) 465 
and 17% (Drummer et al., 2003; Lowenstein & Koziol-McLain, 2001) of drivers injured 466 
or killed in road-traffic accidents test positive for the presence of THC metabolites; this 467 
rate of detection is second only to those driving under the influence of alcohol (Mura et 468 
al., 2003). Indeed, cannabis is considered second only to alcohol for predictive value of 469 
car accidents resulting in death (Li et al., 2012). Of note, rates of drug driving under the 470 
influence of cannabis and consequential rates of injury and death are typically higher 471 
among cohorts of younger, male drivers (Marquet et al., 1998; Mura et al., 2006).  472 
 473 
The potential safety impact of driving under the influence of cannabis has been 474 
demonstrated in numerous experimental (Rafaelsen, Bech, & Rafaelsen, 1973; Ronen et 475 
al., 2010; Ronen et al., 2008), on-road (Ramaekers, Robbe, & O'Hanlon, 2000; Robbe & 476 
O'Hanlon, 1999), meta-analytical (Berghaus, Scheer, & Schmidt, 1995) and review 477 
studies (Hartman & Huestis, 2013; Ramaekers, Berghaus, van Laar, & Drummer, 2004). 478 
These studies indicate highly compromised motor skills and subsequent reductions in 479 
driver safety under both low and high dose cannabis conditions. Specific simulation-480 
based driving studies have demonstrated that low to moderate acute doses of THC (up to 481 
200 µg/kg) result in notable deficits in reaction time (Ronen et al., 2008), visual tracking 482 
ability (Ménétrey et al., 2005), road tracking (weaving) and standard deviation of the 483 
lateral position (SDLP) (Ronen et al., 2008), speed maintenance (Ronen et al., 2010) and 484 
variability (Rafaelsen et al., 1973), and contribute to increased collision rates (Ronen et 485 
al., 2010; Ronen et al., 2008). Some studies, however, have failed to replicate this 486 
magnitude of effect (Anderson, Rizzo, Block, Pearlson, & O'Leary, 2010; Liguori et al., 487 
1998). Several on-road, closed-course driving studies have similarly indicated marked 488 
deficits in driving performance following THC exposure. Specifically, increased SDLP 489 
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(Ramaekers, Robbe, et al., 2000; Robbe, 1998), time driven out of lane (Ramaekers, 490 
Robbe, et al., 2000), standard deviation of headway (Ramaekers, Robbe, et al., 2000), 491 
braking time (Klonoff, 1974), and reduced road tracking and car-following ability have 492 
been observed (Ramaekers, Lamers, Robbe, & O'Hanlon, 2000). Furthermore, research 493 
has indicated a significant dose-response curve under moderate to high THC conditions 494 
(Robbe, 1998), and these effects are considered reflective of measurable THC blood 495 
concentration over time (Papafotiou, Carter, & Stough, 2005). By comparison, the 496 
cognitive-motor effects of newer-generation cannabis-derivative products, such as 497 
medicinal cannabis or cannabis foodstuff, on these parameters are largely understudied 498 
and poorly defined, and thus the potential impact for road safety is unknown.  499 
 500 
Evaluations pertaining to driver culpability (fault) of those involved in road trauma under 501 
the influence of THC are somewhat mixed, with some reporting no increase in culpability 502 
(Longo, Hunter, Lokan, White, & White, 2000; Lowenstein & Koziol-McLain, 2001; 503 
Movig et al., 2004) and others reporting a six-fold increase in the likelihood that THC-504 
affected drivers would be responsible for an incident than THC-unaffected drivers 505 
(Drummer et al., 2004; Lauman, Gadegbeku, Martin, & Biercheler, 2006). Meta-analyses, 506 
however, have largely concluded that, on average, individuals under the influence of THC 507 
are 2.8 times more likely to be involved in road trauma compared to unaffected drivers. 508 
This increased risk is comparable for both fatal and non-fatal collisions (Asbridge, 509 
Hayden, & Cartwright, 2012; Li et al., 2012), as well as for damage to property resulting 510 
from a collision (Elvik, 2013). However, some caution must be made when inferring risk 511 
for crash involvement following cannabis use; due to the toxicological differences 512 
between acute cannabis intoxication and assessments made using the presence of traces of 513 
cannabinoids in samples of blood or urine (used as an indicator of previous use) (Gjerde 514 
& Mørland, 2016). 515 
 516 
Cannabis use produces marked, dose-dependent effects on several safety-sensitive facets 517 
of neurobehavioural performance; which has direct implications for public health. Indeed, 518 
research suggests considerable impairments in numerous acute driving parameters 519 
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following THC administration (Ramaekers et al., 2006), and indicate that its use presents 520 
as a salient risk factor for increased crash-risk and rate of road-trauma involvement 521 
(Asbridge et al., 2012; Drummer et al., 2004; Lauman et al., 2006; Li et al., 2012). 522 
However, additional research investigating specific neuropharmacokinetic and 523 
pharmacodynamic profiles are urgently required to better characterise these associations 524 
and establish reliable models of impairment due to acute intoxication, and if appropriate 525 
multi-platform and targeted preventative strategies are to be employed. This is 526 
particularly important considering the rise in use of newer-generation cannabis products, 527 
including cannabis-based foodstuffs, synthetic cannabis products and medicinal cannabis. 528 
 529 
10. Health benefits of cannabinoids 530 
Despite the extensive adverse effects of cannabis as a whole product, and THC alone, 531 
cannabis is effectively administered for medicinal purposes. It is therefore important to 532 
discuss cannabis in terms of its potential clinical benefits in a therapeutic context. CBD 533 
(cannabidiol) is a non-psychoactive cannabinoid that has been extensively researched for 534 
its therapeutic potential as it has a range of antioxidant, anticonvulsant, anti-inflammatory 535 
and neuroprotective properties (Croxford, 2003; Hampson, Grimaldi, Axelrod, & Wink, 536 
1998; Scuderi et al., 2009). Furthermore, CBD does not elicit any significant cognitive or 537 
psychoactive effect, it is well tolerated as noted in a number of pre-clinical studies, and it 538 
exhibits very low toxicity, even in higher doses (Scuderi et al., 2009).  539 
 540 
The clinical data regarding potential health benefits of CBD are largely derived from 541 
research that evaluates alternative or adjunct treatments for chronic disease where the 542 
existing treatment regime is unsatisfactory or ineffective. Patients with chronic pain, 543 
neurological conditions, such as epilepsy (Devinsky et al., 2016), multiple sclerosis 544 
(Iskedjian et al., 2007), and psychiatric conditions, such as schizophrenia and bipolar 545 
disorder (N. Wilson & Cadet, 2009), have been shown to benefit from a cannabis 546 
intervention. The utility of cannabis as an intervention for chronic pain and epilepsy are 547 
discussed below. 548 
 549 
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10.1. Chronic pain 550 
The clinical utility of CBD as a complementary or alternative mode of treatment for 551 
neurological disorders such as multiple sclerosis has been studied extensively, and the 552 
potential benefit of providing acute symptomatic relief for the chronic and disabling 553 
features of such disorders are widely founded (Iskedjian et al., 2007; Rog, Nurmikko, 554 
Friede, et al., 2005). Indeed, early open-label research assessing the efficacy of CBD 555 
products in treating neuropathic pain associated with advanced multiple sclerosis has 556 
indicated good control of symptoms as a function of treatment, with little tolerability 557 
issues (Rog, Nurmikko, & Young, 2005). These findings have been similarly replicated in 558 
double-blind placebo trials (Rog, Nurmikko, Friede, et al., 2005). Despite these 559 
promising clinical results, the efficacy of this compound to treat neuropathic pain in 560 
multiple sclerosis suffers has been largely inconclusive, which is partly attributable to the 561 
complex nature of the condition, as well as the notable lack of well-designed controlled 562 
studies currently available (Iskedjian et al., 2007; O’Connor et al., 2008). Thus, additional 563 
research is warranted in order to accurately characterise the natural history, mechanisms, 564 
and treatment of pain using CBD treatment in patients with multiple sclerosis, and similar 565 
conditions, in order to better clarify the possible therapeutic potential.  566 
 567 
10.2. Epilepsy 568 
CBD has been effective in the treatment of epilepsy due to the anticonvulsant features of 569 
the compound, the novel mechanisms of action, and the lack of side effects. Early animal 570 
research suggests the antiepileptic activity of CBD is due to its efficacy in reducing or 571 
blocking the motor manifestations of medically-induced convulsions in rats (Chiu, Olsen, 572 
Borys, Karler, & Turkanis, 1979; Karler, Cely, & Turkanis, 1973). Despite these 573 
promising pre-clinical animal studies, there are relatively few comparable human trials, 574 
which may be due to limited patient samples. An early clinical trial conducted by (Cunha 575 
et al., 1980) was perhaps the first controlled clinical trial to evaluate the anticonvulsive 576 
effect of CBD, employing patients who were suffering from treatment resistant secondary 577 
generalised epilepsy with temporal focus. Results indicated that half of those treated with 578 
CBD reported an absence of symptoms for the duration of the trial, and no significant 579 
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toxicity was reported as a result of the treatment. More recent preliminary survey research 580 
has similarly indicated the potential efficacy of CBD as a therapeutic tool for treatment-581 
resistant paediatric epilepsy, with the administration of CBD reported to reduce the 582 
frequency of seizures (Porter & Jacobson, 2013). These findings, however, are derived 583 
from parental observations, thus treatment benefits may be inflated due to personal bias. 584 
Indeed, much of the evidence indicating the therapeutic benefits of CBD in paediatric 585 
populations are largely derived from anecdotal, parental reports or retrospective 586 
assessments, and thus, the true efficacy of the treatment approach remains unclear (Press, 587 
Knupp, & Chapman, 2015; Sirven, 2014). One recently published phase-II uncontrolled 588 
study examining whether the addition of CBD to an existing treatment regime would be 589 
beneficial, finding some evidence for the benefit of the treatment (Devinsky et al., 2016). 590 
It is essential that randomised, controlled clinical trials are conducted, however, before 591 
any real consideration can be given to using CBD as a front-line treatment in groups of 592 
children and adolescents. Concordantly, many governing bodies representing the interests 593 
of epilepsy communities and research, such as the American Epilepsy Society (AES), are 594 
currently opposed to its use until such evidence can be provided. The AES cites issues 595 
with treatment standardization and regulation, dosing requirements, possible long term 596 
adverse side effects and potential medication interactions for complex cases as current 597 
barriers to clinical acceptance and support (American Epilepsy Society, 2016).  598 
 599 
Evidently, there are some positive outcomes associated with cannabis use, however, these 600 
may largely result from the efficacy of CBD. Furthermore, the reliability of clinical trials 601 
that investigate the medicinal efficacy of cannabis has come into question due to the 602 
highly prevalent placebo effect, which is accentuated by subjective symptom severity 603 
reporting measures, the positive reputation of cannabis and subsequent patient 604 
expectations, and the acute psychiatric effects of cannabis (Russo, 2016). Further research 605 
into the efficacy of cannabis and CBD is needed to ensure that the benefits of cannabis 606 
use do not outweigh the potential costs. 607 
 608 
11. Synthetic ‘Spice’ cannabinoids 609 
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Products containing synthetic cannabinoids (also known as K2 or Spice, hereafter referred 610 
to as Spice) are high-potency, high-efficacy, CB1 cannabinoid-receptor agonists, and are 611 
often marketed under the pretence of being a benign substance, such as potpourri or 612 
incense (Spaderna, Addy, & D’Souza, 2013). Unlike organic forms of the Cannabis 613 
Sativa plant, synthetic cannabis does not contain cannabidiol, which exhibits both 614 
anxiolytic and antipsychotic properties (Croxford, 2003). Although the Spice is marketed 615 
as ‘not for human consumption’ in order to circumvent drug laws and regulation, it is 616 
generally purchased for the purpose of intoxication (Vardakou, Pistos, & Spiliopoulou, 617 
2010). These products are generally inhaled (smoked), and can be ingested as a liquid 618 
(Vardakou et al., 2010). The use of these ‘designer cannabinoid’ products was first 619 
reported in Europe in the mid-2000’s, then spread to the Americas and elsewhere 620 
(Spaderna et al., 2013). Consumption of Spice is considered to be increasing, which is 621 
likely driven by the ease of availability and novelty of the product among first-time users 622 
(Dargan, Hudson, Ramsey, & Wood, 2011; Schifano et al., 2010), as well as it delivering 623 
a relatively cheap ‘legal high’ and the inability of traditional urine drug screens to detect 624 
use (Seely, Lapoint, Moran, & Fattore, 2012).  625 
 626 
Despite the general increase in the use of Spice, accurate descriptions regarding its 627 
adverse effects and toxicological profile are currently lacking. The acute effects of Spice 628 
are typically significantly stronger than for natural cannabis products (Kronstrand, 629 
Roman, Andersson, & Eklund, 2013), and sometimes lead to severe psychological and 630 
psychophysiological effects, including tachycardia/hypertension, visual/auditory 631 
hallucination, mydriasis, agitation/anxiety, tachypnea, nausea/vomiting, and seizures 632 
(Papanti, Orsolini, Francesconi, & Schifano, 2014). Indeed, the acute use of Spice has 633 
been reported to cause severe respiratory depression requiring intubation (Jinwala & 634 
Gupta, 2012), contributing to cases of myocardial dysfunction (Mir, Obafemi, Young, & 635 
Kane, 2011) and stroke (Hoyte et al., 2012), and has even been cited as a primary cause of 636 
death (Kronstrand et al., 2013). The adverse chronic effects of Spice are also similar to 637 
those of the natural plant product, including panic, anxiety, catatonia, psychosis, and a 638 
range of ‘bizarre behaviours’ and disordered cognition (Gurney, Scott, Kacinko, Presley, 639 
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& Logan, 2014; Vandrey, Dunn, Fry, & Girling, 2012). The psychosis associated with 640 
these synthetic cannabinoids has been colloquially termed ‘Spiceophrenia’ (Papanti et al., 641 
2013), and the pathological profile is considered comparable to that observed in cases of 642 
drug-induced psychosis, involving symptoms of severe agitation, disorganised thoughts, 643 
paranoid delusions, and assaultive behaviour. One inherent and ongoing difficulty in 644 
effectively characterizing both the acute and long-term effects, as well as the 645 
toxicological profile, of commercially available Spice, is due the broad range of 646 
ingredients often included in the packets. Often, many of the included ingredients differ 647 
substantially in regard to the mechanistic profile and neurobiological actions of the 648 
compounds between products. These compounds used are frequently altered in response 649 
to local and federal legislative changes implemented to stop the legal purchase of these 650 
products. Thus, flexible and ongoing monitoring of available marketed products is 651 
necessary if appropriate policing efforts and current recommendations are to be 652 
implemented and adhered to.  653 
 654 
12. Conclusions 655 
Proponents for cannabis have largely focused on its acute effects as a relaxant and 656 
euphoriant. This narrow focus is misleading and often undermines the considerable 657 
literature base demonstrating the adverse effects of the substance. Both the acute and 658 
chronic effects should be considered when debating the overall efficacy of cannabis as a 659 
recreational and therapeutic substance. Indeed, if one focused on acute drug effects, 660 
psychoactive drugs in general would be misperceived as beneficial as the effect on-drug is 661 
typically more desirable than off-drug (Parrott et al., 2008). The same principal applies to 662 
caffeine, alcohol and nicotine. However, negative acute effects, such as disordered 663 
thoughts and cognitions, fear of dying, panic and increased PANSS symptoms, are 664 
reported (Ashton, 2001; Crean et al., 2011; D'Souza et al., 2004; Volkow et al., 2014). 665 
These negative effects are largely due to the high concentration of THC in recreational 666 
cannabis (Crean et al., 2011; United Nations Office of Drugs and Crime, 2016; Volkow et 667 
al., 2014). THC is also largely responsible for the detrimental effects of regular drug use 668 
(Crean et al., 2011; Volkow et al., 2014). One of the core paradoxes of recreational drug 669 
 24 
usage is that while acute effects tend to be positive, chronic effects are largely negative; 670 
hence the well-documented adverse effects of regular alcohol, nicotine, cocaine and 671 
methamphetamine, and heroin consumption (Cadet, Krasnova, Jayanthi, & Lyles, 2007; 672 
Cruickshank & Dyer, 2009; Parrott, 1999, 2013; Parrott et al., 2008).  673 
 674 
Weekly recreational use of cannabis progresses to substance dependence and chronic use 675 
in 17% of cases (Coffey et al., 2003). Risk factors for dependence include avoidance of 676 
withdrawal symptoms, compulsive use and tolerance (Coffey et al., 2002; Coffey et al., 677 
2003), while mood and psychiatric conditions have been shown to increase likelihood of 678 
substance initiation (Coffey et al., 2003; N. Wilson & Cadet, 2009), and symptoms 679 
severity have been associated with increased use (Volkow et al., 2014; N. Wilson & 680 
Cadet, 2009; Wittchen et al., 2007). 681 
 682 
Additional effects of chronic cannabis use include adverse neurocognitive (D'Souza et al., 683 
2004; Grant et al., 2003; Jager et al., 2010; Pope et al., 2001; Ramaekers et al., 2008), 684 
neurological (Batalla et al., 2013; Battistella et al., 2014; Lorenzetti et al., 2014; 685 
Lorenzetti et al., 2016), respiratory and cardiovascular (Benowitz & Jones, 1975; Sidney, 686 
2002; Wolff et al., 2011), cancer (Aldington et al., 2008; Llewellyn et al., 2004; Zhang et 687 
al., 1999) and pregnancy outcomes (Grufferman et al., 1993; Kuijten et al., 1990; Robison 688 
et al., 1989). Extensive evidence also suggests that smoking cannabis leads to similar 689 
cardiovascular and cancer outcomes as cigarette smoking (Aldington et al., 2008; 690 
Aldington et al., 2007; Ashton, 2001; Taylor & Hall, 2003). However, this may be due in 691 
part to a moderating effect of tobacco, as cannabis is often combined with tobacco to be 692 
smoked, which is seldom controlled for.  693 
 694 
It is important to recognise that although consumption of cannabis has significant adverse 695 
health effects, specific cannabinoids, such as CBD, appear to have significant benefits 696 
due to its antioxidant, anticonvulsant, anti-inflammatory and neuroprotective properties 697 
(Croxford, 2003; Hampson et al., 1998; Scuderi et al., 2009). Although, clinical trials are 698 
at risk of demonstrating a placebo effect, due to the subjective nature of symptom 699 
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measures, the positive expectations of cannabis, and its acute psychiatric effects (Russo, 700 
2016). Hence, we strongly support research into the potential benefits of specific 701 
cannabinoids.  702 
 703 
With rapidly shifting social and legal policies in a number of jurisdictions across the 704 
world, the use of cannabis is likely to increase in some regions. Consequently, an increase 705 
in adverse health, psychobiological, educational, and psychosocial outcomes for 706 
individuals is inevitable (Volkow et al., 2014). These outcomes have roll on effects on the 707 
health, safety and welfare of the community, for example, in terms of road safety. 708 
Although there are many potential benefits for the legalisation and regulation of cannabis, 709 
educating the global community about the widespread adverse effects of cannabis 710 
consumption is important. 711 
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